Enhancing effect of chitosan on peptide drug delivery across buccal mucosa

Şenel, Sevda; Kremer, Mary; Kaş, S; Wertz, Philip W.; Hıncal, A. Atilla; Squier, Christopher A.

doi:10.1016/s0142-9612(00)00134-4

Cited by 235 publications

(106 citation statements)

References 16 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…We chose chitosan as a carrier for DNA encapsulation because DNA plasmids are negatively charged and chitosan (cationic polypeptides) are positively charged, which enhances bioadhesivity and site-specific applications in controlled delivery systems. 25,38 Therefore, microspheres/nanoparticles can increase the residence time of drugs in the nasal mucosa compared with solutions, and exert a direct effect on the nasal mucosa, resulting in the opening of tight junctions between the epithelial cells. 39 It should be noted that microspheres/nanoparticles have been proven as an effective carrier for the delivery of drugs in nasal administration.…”

mentioning

confidence: 99%

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Zhao¹,

Zhang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

Optimal preparation conditions of Newcastle disease virus (NDV) F gene deoxyribonucleic acid (DNA) vaccine encapsulated in chitosan nanoparticles (pFNDV-CS-NPs) were determined. The pFNDV-CS-NPs were prepared according to a complex coacervation method. The pFNDV-CS-NPs were produced with good morphology, high stability, a mean diameter of 199.5 nm, encapsulation efficiency of 98.37%±0.87%, loading capacity of 36.12%±0.19%, and a zeta potential of +12.11 mV. The in vitro release assay showed that the plasmid DNA was sustainably released from the pFNDV-CS-NPs, up to 82.9%±2.9% of the total amount. Cell transfection test indicated that the vaccine expressed the F gene in cells and maintained good bioactivity. Additionally, the safety of mucosal immunity delivery system of the pFNDV-CS-NPs was also tested in vitro by cell cytotoxicity and in vivo by safety test in chickens. In vivo immunization showed that better immune responses of specific pathogen-free chickens immunized with the pFNDV-CS-NPs were induced, and prolonged release of the plasmid DNA was achieved compared to the chickens immunized with the control plasmid. This study lays the foundation for the further development of mucosal vaccines and drugs encapsulated in chitosan nanoparticles.

show abstract

mentioning

confidence: 99%

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Zhao¹,

Zhang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…The enhancer activity of CH on the buccal, 22) nasal, 23) rectal 24) and intestinal mucosa 25) have been reported. The mechanism of action of the CH was suggested to be a combination of bioadhesion and a transient widening of the tight junctions in the membrane.…”

Section: Resultsmentioning

confidence: 99%

Transdermal Administration of Bromocriptine.

Değim

Acartürk

Erdoğan

et al. 2003

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Bromocriptine (BRC) is a semi-synthetic ergot alkaloid and it has been used for the treatment of diseases caused by hyperprolactinemia and for some neurological disorders as a dopamine agonist in clinics.1) BRC is mainly used for the inhibition of lactation, 2) treatment of menstrual disorders, 3) Parkinson disease, 4) breast tumours, 5) infertility 6) and brain tumours. 7)Bromocriptine is well absorbed through the GI tract but it has low bioavailability because of the hepatic first pass effect, but many patients have complained with GI side effects, headache and dizziness.4) The long acting injectable form of BRC has been developed 2) and it avoids the gastrointestinal side effects but it is expensive and cannot be self-administered.An alternative delivery route such as vaginal application of BRC has been reported. 8,9) Bromocriptine is well absorbed from vagina. Acartürk and Altug have studied the vaginal ring formulation of BRC with polydimethylsiloxane in vitro and in vivo in rabbits. 10,11) It was shown that the controlled release intravaginal ring containing BRC was found to be effective to decrease the plasma prolactin level in rabbits.BRC has also used for the treatment of Parkinson disease and the transdermal administration may be more useful than vaginal administration, being not gender limited. Transdermal delivery of drugs is also very convenient from the application point of view and it offers several advantages over the other routes of drug administration and termination of the drug input is possible in problematic cases. 12,13) Transdermal systems represent one of the most successful non-oral systemic drug delivery system. However, because of limitations of the technology, the physical, chemical nature of the compounds and also lack of the knowledge about penetration mechanisms, transdermal drug delivery is not suited to all drugs and it needs to be justified for the therapies.14)The penetration mechanisms, histopathological hazards of the enhancers and vehicles need to be clarified.The aim of this study was to investigate an alternative delivery route for BRC. Several topical BRC gel formulations were developed using Carbopol (C-934), Daichitosan (CH) and Gantrez-SP215 (G-SP215) and applied to rabbits. Commercially available BRC tablets (Parlodel ® ) were also given to rabbits orally and plasma levels were compared. Two different penetration enhancers, sodium taurocholate (ST) and ethoxydiglycol-Transcutol ® (TR) were also used to improve BRC penetration. Preparation of Gel Formulations For formation of the gel, CH or C-934 was dispersed in water then acetic acid or 0.01 N NaOH was added, respectively. BRC was dissolved in absolute ethanol and then mixed with the gel. TR or ST was added for the preparation of CH-ST or CH-TR gel. G-SP215 solution in ethanol was neutralised by triethanolamine and mixed with BRC solution in ethanol. Bromocriptine (BRC) has been mainly used for the inhibition of lactation, treatment of menstrual disorders, Parkinson disease, breast tumours, infertility and brain tumo...

show abstract

“…What is more, hipocholesterolemic, hipolipidemic [32], antimicrobial [33] and antitumor activity [34] of chitosan have been reported. It is very often used for encapsulating enzymes [35], in dentistry [36], but also to manufacture matrices for drug delivery [37].…”

Section: Biopolymers Used In Microencapsulationmentioning

confidence: 99%

Wytwarzanie homo- i heterogenicznych mikrokapsułek oraz ich zastosowanie

Semba

Trusek-Hołownia

2017

View full text Add to dashboard Cite

Microencapsulation is defined as a process during which the whole envelopment with (bio)catalysts, substrates etc. is included into hydrogel and/or surrounded by a porous polymeric membrane. However, the production of homogeneous, narrow size, distributed capsules is quite troublesome. The main problem is the way of obtaining a large number of capsules with a precisely predefined size. It is possible due to a device called an encapsulator. This equipment allows to produce homogeneous beads and core-shell systems with a predefined size in the range from 400 µm to 1600 µm, which is possible because of special nozzles with different diameters. There are a lot of microcapsule applications. In this paper, we would like to present the construction, principles of operation and selected applications of microencapsulation devices using the example of the BÜCHI-B390 encapsulator.Keywords: microencapsulation; homogeneous beads; core-shell systems; encapsulator BÜCHI-B390 Streszczenie Mikrokapsułkowanie definiowane jest jako proces, w którym całe środowisko zawierające m.in. (bio)katalizatory, substraty itp. zamykane jest w sieci hydrożelu i/lub otaczane porowatą polimerową membraną. Wytwarzanie jednorodnych kapsułek o wąskim rozkładzie wielkości jest dość kłopotliwe. Głównym problemem do rozwiązania jest sposób uzyskania dużej liczby kapsułek o dokładnie zdefiniowanej wielkości. Jest to możliwe przy użyciu urządzenia zwanego enkapsulatorem. Pozwala ono na wytwarzanie homogenicznych kapsułek i układów rdzeń-powłoka o zdefiniowanej wielkości w zakresie od 400 µm do 1600 µm, co jest możliwe za pomocą zestawu dysz o różnych średnicach. Istnieje wiele aplikacji mikrokapsułek. W artykule przedstawiona zostanie budowa, zasada działania i wybrane zastosowania urządzenia do mikroenkapsulacji na przykładzie enkapsulatora BUCHI-B390.Słowa kluczowe: mikroenkapsulacja; homogeniczne mikrokapsułki; układy rdzeń-powłoka; enkapsulator BÜCHI-B390

show abstract

Enhancing effect of chitosan on peptide drug delivery across buccal mucosa

Cited by 235 publications

References 16 publications

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Transdermal Administration of Bromocriptine.

Wytwarzanie homo- i heterogenicznych mikrokapsułek oraz ich zastosowanie

Contact Info

Product

Resources

About